Cryo-Cell International Inc (CCEL)
AMEXHealth CareMedical - Care FacilitiesSnapshot 2026-09-04
$4.28+0.94%
Close 2026-09-04 · 1-day change
AMEXHealth CareMedical - Care FacilitiesSnapshot 2026-09-04
QuarterlyIQ Insights · CCEL
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Nov 2025 | Nov 2024 | Nov 2023 | Nov 2022 | Nov 2021 | Nov 2020 | Nov 2019 | Nov 2018 | Nov 2017 | Nov 2016 | Nov 2015 | Nov 2014 | Nov 2013 | Nov 2012 | Nov 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | 31.1 | 31.6 | 32.0 | 31.3 | 30.3 | 28.9 | 31.1 | 31.8 | 29.2 | 25.4 | 23.1 | 21.1 | 20.1 | 19.0 | 18.0 | 17.9 |
| Total Revenues | — | — | — | — | — | — | — | — | — | 25.4 | 23.1 | 21.1 | 20.1 | 19.0 | 18.0 | 17.9 |
| Cost of Revenues | 6.9 | 7.4 | 7.9 | 8.4 | 8.8 | 9.0 | 9.7 | 10.0 | 8.5 | — | — | — | — | — | — | — |
| Operating Expenses & Income | ||||||||||||||||
| Selling, General & Admin | 19.0 | 18.2 | 18.5 | 17.2 | 15.6 | 14.6 | 14.3 | 14.9 | 15.6 | 13.5 | 14.7 | 12.4 | 12.3 | 11.4 | 14.4 | 12.4 |
| R&D Expenses | 0.3 | 0.4 | 1.2 | 1.2 | 0.4 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.1 | 0.0 | 0.1 | 0.0 | 0.1 | 0.2 |
| Operating Income | (0.1) | 0.5 | 3.5 | (12.3) | 4.0 | 4.0 | 7.7 | 5.1 | 5.2 | 5.0 | 0.4 | 2.9 | 2.0 | 1.7 | (1.7) | (0.3) |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | 1.9 | 2.1 | 1.9 | 1.2 | 1.5 | 1.4 | 1.5 | 1.7 | 1.5 | 1.3 | 0.9 | 1.3 | 1.2 | 1.4 | 1.0 | 1.5 |
| Interest & Investment Income | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.1 | 0.0 |
| Net Interest Expenses | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 1.0 | 1.4 |
| Other Non-Operating Income / Expenses | (2.4) | (2.8) | (0.7) | (1.1) | (0.7) | (1.4) | (2.6) | (1.7) | (1.6) | (1.4) | (2.9) | (2.0) | (0.9) | (1.4) | (2.6) | (1.4) |
| Asset Writedown | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.6 |
| EBT, Incl. Unusual Items | (2.5) | (2.3) | 2.8 | (13.4) | 3.3 | 2.6 | 5.0 | 3.4 | 3.6 | 3.6 | (2.5) | 1.0 | 1.0 | 0.4 | (4.3) | (1.7) |
| Income Tax Expense | (0.1) | 0.1 | 2.4 | (3.8) | 0.5 | 0.5 | 1.4 | 1.1 | 4.5 | 1.3 | (1.2) | (7.2) | 0.1 | 0.2 | 1.9 | 0.2 |
| Net Income | ||||||||||||||||
| Net Income | (2.5) | (2.4) | 0.4 | (9.5) | 2.8 | 2.1 | 3.6 | 2.3 | (0.9) | 2.3 | (1.3) | 8.1 | 0.6 | 0.0 | (6.3) | (2.1) |
| Per Share | ||||||||||||||||
| Basic EPS | (0.31) | (0.30) | 0.05 | (1.14) | 0.33 | 0.26 | 0.48 | 0.29 | (0.11) | 0.33 | (0.16) | 0.85 | 0.05 | 0.00 | (0.56) | (0.18) |
| Diluted EPS | (0.31) | (0.30) | 0.05 | (1.14) | 0.33 | 0.25 | 0.45 | 0.27 | (0.11) | 0.30 | (0.16) | 0.83 | 0.05 | 0.00 | (0.56) | (0.18) |
| Revenue per Share | 3.86 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Dividend per Share | — | — | 0.25 | — | 0.90 | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 8.1 | 8.1 | 8.1 | 8.3 | 8.5 | 8.1 | 7.5 | 7.8 | 7.5 | 7.1 | 8.1 | 9.5 | 10.2 | 10.9 | 11.3 | 11.8 |
| Diluted Weighted Avg Shares | 8.1 | 8.1 | 8.2 | 8.3 | 8.5 | 8.4 | 8.1 | 8.4 | 7.5 | 7.7 | 8.1 | 9.8 | 10.4 | 11.0 | 11.3 | 11.8 |
| Supplemental | ||||||||||||||||
| EBITDA | — | 1.2 | 4.0 | (11.2) | 5.1 | 4.9 | 7.8 | 5.3 | 5.4 | 5.1 | 0.6 | 3.0 | 2.2 | 1.9 | (1.5) | 0.1 |
| EBIT | (0.1) | 0.5 | 3.5 | (12.3) | 4.0 | 4.0 | 7.7 | 5.1 | 5.2 | 5.0 | 0.4 | 2.9 | 2.0 | 1.7 | (1.7) | (0.3) |
| Effective Tax Rate | 3.2% | — | — | 28.8% | 16.5% | 20.2% | 28.1% | 32.5% | 123.6% | 36.1% | 46.7% | -739.1% | 11.9% | 48.3% | -44.3% | -10.1% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.